DURECT Corporation - Drug delivery technologies treating chronic debilitating disease

Page Not Found

Contact

Site Map

Legal Notice

Corporate Policies/Governance

Business Development Approach

The SABER™ Delivery System

ORADUR® Gel-Cap System

TRANSDUR™ Transdermal Technology System

DURIN™ System

DUROS® System

MICRODUR™ System

Localized Drug Delivery

Patents

Stock Information

Corporate Presentation

DURECT: Developing products to treat chronic debilitating disease and technologies that enable biotechnology products.

Indication:

Focus:

Post-Herpetic Neuralgia

ELADUR™
Is a sustained release formulation of bupivacaine using our TRANSDUR™ technology to provide pain relief for patients suffering from Post-Herpetic Neuralgia (post-shingles pain or PHN).

Learn more
View complete product pipeline

March 01, 2010
DURECT to Present at the Cowen and Company Healthcare Conference

February 24, 2010
DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results

February 22, 2010
DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory

	2008 Annual Report
	2007 Annual Report
	2006 Annual Report
	2005 Annual Report

Last updated: December 21, 2009
built@zoomedia.com

Contact

Site Index

Legal Notice